Kalaris Therapeutics Azioni (NASDAQ: KLRS)

Kalaris Therapeutics (NASDAQ:KLRS) Azioni

Kalaris Therapeutics

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics Inc

Benchmark analyst Fawne Jiang maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $58 to $53.

News

Price Target

Analyst Ratings

Benchmark Maintains Buy on JD.com, Lowers Price Target to $53

Scotiabank analyst Orest Wowkodaw maintains Nexa Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) with a Sector Underperform and raises the price target from $4.5 to $5.

NEXA

Scotiabank Maintains Sector Underperform on Nexa Res, Raises Price Target to $5

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib
Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expected 4Q 2025
FOSTER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting the potential of TERN-701 as a treatment for chronic myeloid leukemia (CML) will be highlighted in an oral presentation at the 30th European Hematology Association Congress (EHA25) taking place from June 12-15, 2025 in Milan, Italy.
TERN-701 is an investigational next-generation allosteric BCR-ABL inhibitor specifically targeting the ABL myristoyl pocket. The preclinical data to be presented highlight the potency of TERN-701 on more than 20 clinically relevant resistance mutations in the active-site, P-loop, and allosteric regions of the BCR-ABL oncoprotein, and provide additional data characterizing the drug-like properties of TERN-701 and supporting the potential to provide meaningful clinical benefits over existing therapies.

Biotech

General

TERN

Terns Pharmaceuticals Selected For Oral Presentation At EHA Congress For Preclinical Data On Novel Allosteric BCR-ABL Inhibitor TERN-701

Septerna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced an exclusive global collaboration and license agreement on Wednesday.
The pact covers discovering, developing, and commercializing oral small-molecule medicines for obesity, type 2 diabetes, and other <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cardiometabolic diseases</a>.
The companies <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916006" target="_blank" rel="noreferrer noopener">will</a> initially commence four development programs. 
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45347237/novo-nordisks-sogroya-supports-effective-weekly-alternative-to-daily-hormone-therapy-across-three-growth-disorders" rel="noreferrer noopener">Novo Nordisk&#8217;s Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders</a>
GPCRs represent the largest and most diverse family of cell membrane receptors, with hundreds of different GPCRs regulating physiological processes in nearly every organ system of the human body.
Using its proprietary Native Complex Platform, Septerna aims to unlock the full potential of GPCR therapies. The company is focused on discovering and developing a pipeline of oral small molecules for multiple therapeutic areas.
Septerna is eligible to receive approximately $2.2 billion across an upfront payment, R&amp;D, and commercial milestone payments. It also includes over $200 million in upfront and near-term milestone payments.
Septerna can also receive tiered royalties on global net sales of marketed products. Under the collaboration, Novo Nordisk will cover all research and development expenses for partnered programs.
The companies will jointly conduct research activities from discovery through candidate selection.
Starting with IND-enabling activities, Novo Nordisk will be solely responsible for all global development and commercialisation activities. In addition, Septerna has the right to opt in to a worldwide profit share for one program in the collaboration in lieu of future milestones and royalties for that product candidate.
On Tuesday, secondary post hoc <a target="_blank" href="https://www.prnewswire.com/news-releases/in-new-select-trial-analysis-early-reduction-in-cardiovascular-events-was-observed-with-wegovy-before-clinically-meaningful-changes-in-body-weight-302453751.html" rel="noreferrer noopener">analysis</a> of Novo Nordisk&#8217;s SELECT trial showed that within the first three months of Wrgovy treatment, reductions in the risk of MACE in adults with obesity and established cardiovascular disease (CVD) were seen.
Reductions were also observed within six months in the risk of dying from CVD or being hospitalized or needing urgent medical attention due to heart failure.
Data showed that within six months of treatment, a reduction in risk of CV death was observed for patients taking Wegovy&nbsp;related to CV death; lowered composite heart failure risk, and reduced death from any cause.
Price Action: Septerna stock is up 63.08% at $10.98. Novo Nordisk stock is up 1.87% at $66.62 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii&#8217;s Plavix Lawsuit</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Contracts

Movers

Trading Ideas

SEPN

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) will release its third-quarter financial results after the <a href="https://www.benzinga.com/quote/csco/earnings">closing bell on Wednesday, May 14.</a>
Analysts expect the San Jose, California-based company to report quarterly earnings at 92 cents per share, up from 88 cents per share in the year-ago period. Cisco projects quarterly revenue of $14.06 billion, compared to $12.7 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst estimates for revenue in more than 10 straight quarters.
Cisco shares gained 0.2% to close at $61.78 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Evercore ISI Group analyst Amit Daryanani maintained an Outperform rating and cut the price target from $75 to $67 on April 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Rosenblatt analyst Mike Genovese maintained a Buy rating and cut the price target from $80 to $63 on April 22, 2025. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Samik Chatterjee maintained an Overweight rating and cut the price target from $73 to $70 on April 17, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Citigroup analyst Atif Malik maintained a Buy rating and slashed the price target from $73 to $68 on April 14, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Piper Sandler analyst James Fish maintained a Neutral rating and cut the price target from $72 to $60 on April 8, 2025. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14030338/image-151-1024x572.png" alt="" class="wp-image-914502" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14030338/image-151-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14030338/image-151-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14030338/image-151-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14030338/image-151.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

CSCO

Cisco Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Qnity&#x2122; Branding Symbolizes the Power of Innovation and Partnership
WILMINGTON, Del., May 14, 2025 /PRNewswire/ -- DuPont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) today unveiled the branding of Qnity, the planned independent Electronics public company that will be created through the intended spin-off of its Electronics business&#x2A;. As a pure-play electronics materials company, Qnity will be one of the largest and broadest solutions providers to the semiconductor and electronics industries enabling advanced computing, smart technologies and connectivity. Qnity (pronounced cue-ni-tee) is inspired by 'Q', the symbol for electrical charge, and 'unity'.

Dupont Unveils Branding Of Qnity, Planned Independent Electronics Public Company To Be Created Through Intended Spin-off Of Electronics Business

Scotiabank analyst Orest Wowkodaw maintains Lundin Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LUN#TSX">LUN</a>) with a Sector Outperform and raises the price target from C$14 to C$14.5.

TSX:LUN

Scotiabank Maintains Sector Outperform on Lundin Mining, Raises Price Target to C$14.5

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.19% to 42,218.65 while the NASDAQ gained 0.65% to 19,133.96. The S&amp;P 500 also rose, gaining, 0.29% to 5,903.54.
Check This Out: <a href="https://www.benzinga.com/25/05/45402795/top-3-materials-stocks-that-could-blast-off-this-month">Top 3 Materials Stocks That Could Blast Off This Month</a>
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Wednesday.
In trading on Wednesday, utilities stocks fell by 1.1%.
Top Headline
Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported better-than-expected fourth-quarter EPS results.
Sony Group reported quarterly earnings of 21 cents per share which beat the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $17.25 billion which missed the analyst consensus estimate of $20.40 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares shot up 376% to $0.4092 after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.</li>
<li>Shares of Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) got a boost, surging 63% to $10.99 after the company announced an exclusive global collaboration and license agreement with Novo Nordisk to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) shares were also up, gaining 53% to $1.8390.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares dropped 41% to $0.0169.</li>
<li>Shares of TEN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) were down 37% to $0.8601.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) was down, falling 37% to $0.0525.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $63.03 while gold traded down 1.7% at $3,191.50.
Silver traded down 2.2% to $32.390 on Wednesday, while copper fell 0.7% to $4.6895.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.1%, while Spain's IBEX 35 Index rose 0.4%. London's FTSE 100 rose 0.1%, Germany's DAX 40 fell 0.2% and France's CAC 40 slipped 0.3% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei falling 0.14%, Hong Kong's Hang Seng Index gaining 2.30%, China's Shanghai Composite Index gaining 0.86% and India's BSE Sensex gaining 0.22%.
Economics
U.S. mortgage application volumes increased by 1.1% from the previous week in the week ending May 9, following an 11% surge in the prior period.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Intraday Update

AXDX

IXHL

PLRZ

Sony Group Corporation American Depositary Shares

SONY

XHLD

Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14091726/Zijin-Mine.jpeg" alt="" class="wp-image-12926" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14091726/Zijin-Mine.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14091726/Zijin-Mine-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14091726/Zijin-Mine-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company hopes to take advantage of record gold prices to raise big money from a separate listing for its overseas business mining the precious metal
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Zijin Mining has announced a plan to spin off its overseas gold assets, which account for nearly 70% of its total gold production</li>
<li>Revenue from the company's gold mining business represented around half of its total last year</li>
</ul>
Stocks may be fine in normal times, but in turbulent times like now – plagued by geopolitical tensions, inflationary pressure and falling interest rates – gold is glowing more by the day as an investor safe haven. That's lit a fire under the precious metal, whose price surged to a record high of $3,500 per ounce in April, up more than 30% year-to-date, becoming an investor favorite lately.
As that happens, leading Chinese gold producer&nbsp;Zijin Mining Group Co. Ltd.&nbsp;(2899.HK; 601899.SH) has&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0430/2025043003439.pdf">announced</a>&nbsp;plans to milk its offshore gold assets by separately listing them in a Hong Kong company. Such a plan would see it reorganize its assets by moving several major gold mines in South America, Central Asia and Oceania into its&nbsp;Zijin Gold International Inc.&nbsp;subsidiary, which would get listed through an IPO. It's a classic case of "striking while the iron is hot," by taking advantage of the recent upswing in gold prices.
Zijin said the move would accelerate its internationalization, strengthen its capital management efficiency and enhance its capacity for offshore financing and M&amp;A. After the spinoff, Zijin Mining will continue to control Zijin Gold International, and will consolidate the latter's financials into its own statements.
<h4 class="wp-block-heading">Booming business</h4>
Gold is a major contributor to both Zijin Mining's revenue and profits. Its 2024 annual financial report shows that gold was the company's biggest revenue spinner last year, accounting for 49.64% of its total revenue.
Gold contributed 30.07% of the company's gross profit for the year, significantly higher than the contribution by other metals in its portfolio. Its total gold output last year reached 72.94 tons, up 7.7% year-on-year. Around 65.5% of its gold production came from overseas mines, including the Buriticá gold mine in Colombia, the Norton gold fields in Australia and the Rosebel gold mines in Suriname.
Zijin also leads in terms of its gold-production capacity and size of its gold reserves. It produced 72.94 tons of gold last year, up 7.7% year-on-year, bringing the compound annual growth rate for its gold output to 12% over the past five years. It mined 19.07 tons of gold in the first quarter of this year, up 13% year-on-year. And it raised its target output for the whole year to 85 tons, up 16% from last year.
Data from the China Gold Association shows China produced 298.4 tons of gold in 2024, with Zijin accounting for 24% of that. The company's gold reserves reached 3,483.7 tons by the end of last year, ranking it sixth in the world on that basis.
As is often the case for miners when their commodity prices rise, booming gold prices provided a lift for Zijin's business last year – especially on its bottom line. Its revenue rose 3.5% year-on-year to 303.64 billion yuan, while its net profit jumped 51.76% to a record 32.05 billion yuan, well ahead of the 27% rise in global gold prices during the year. The gross margin for its mining products jumped to 57.97%, up 8.88 percentage points from last year, as the company reaped bigger profits for each ounce of gold it mined due to rising prices.
The growth continued in the first quarter of 2025, when the company reported its revenue rose 5.5% year-on-year to 78.93 billion yuan. Its net profit jumped 62.39% to 10.17 billion yuan, marking the first time breaking through the 10 billion yuan mark. Global gold prices rose about 20% during the period, cresting at the $3,500 record high in late April.
<h4 class="wp-block-heading">Investor appeal of overseas mines</h4>
From a strategic perspective, the international asset spinoff is not just an attempt at asset re-rating, but also a forward-looking move for Zijin's capital management over the longer run. Once its separate listing is complete, Zijin Gold International will be able to act as Zijin Mining's primary platform for gold resource acquisition and overseas capital management, which will help reduce the parent's financial burden and geopolitical risk exposure.
A Hong Kong IPO would also allow the newly listed international company to benchmark itself against industry leaders such as&nbsp;Newmont&nbsp;(NEM.US) and&nbsp;Barrick Gold&nbsp;(GOLD.US), in a bid to gain a better valuation than its parent. As an independent entity, Zijin Gold International would have a very strong asset base, accounting for close to 70% of its parent's total gold output, which could justify such a strong potential valuation.
South America is one of Zijin's fastest-growing gold-producing regions, accounting for around 30% of the company's total gold output last year from four gold mines that generated 21.6 tons of the precious metal. A successful spinoff and separate listing would allow Zijin Gold International to become a pure gold play, and an attractive component stock for the world's many gold ETFs and index funds.
High investor hopes are reflected in Zijin Mining's stock. On the day of the spinoff announcement, the company's Shanghai- and Hong Kong-listed shares rose 1.7% and 1.3%, respectively, signaling optimism on the initiative. Many see the move as a way to attract more investors looking for pure gold plays, while a high valuation for the new company could also help to lift Zijin Mining's own stock.
At the end of the day, executing the spinoff as gold prices are surging looks smart not only from a capital management perspective, but also as a way to better navigate competition for global resources in a changing geopolitical landscape. For investors, Zijin Gold International's separate listing will open up a new channel for investment in China's overseas gold resources, which might lead to higher valuations for its gold mining assets, as well as better engagement with international capital.

Asia

IPOs

Opinion

Zijin Mining Seeks Hong Kong IPO For Offshore Assets

Scotiabank analyst Mario Saric maintains Killam Apartment REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KMP#TSX">KMP</a>) with a Sector Perform and raises the price target from C$20.5 to C$20.75.

TSX:KMP

TSX:KMP/UN

Scotiabank Maintains Sector Perform on Killam Apartment REIT, Raises Price Target to C$20.75

Brenntag (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BNTGY#OTC">BNTGY</a>) reported quarterly earnings of $0.20 per share. This is a 4.76 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $4.28 billion in sales this quarter. This is a 1.50 percent decrease over sales of $4.35 billion the same period last year.

BNTGY

Brenntag Q1 EPS $0.20 Down From $0.21 YoY, Sales $4.28B Down From $4.35B YoY

Benchmark analyst Fawne Jiang maintains Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) with a Buy and raises the price target from $150 to $180.

Benchmark Maintains Buy on Sea, Raises Price Target to $180

Subaru (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUJHY#OTC">FUJHY</a>) reported quarterly earnings of $0.10 per share. This is a 74.36 percent decrease over earnings of $0.39 per share from the same period last year. The company reported $7.54 billion in sales this quarter. This is a 7.31 percent decrease over sales of $8.13 billion the same period last year.

FUJHY

Subaru Q4 Earnings Per ADS of $0.10 Down From $0.39 YoY, Sales $7.54B Down From $8.13B YoY

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

Scotiabank analyst Orest Wowkodaw maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Sector Outperform and raises the price target from C$12.5 to C$14.

TSX:HBM

Scotiabank Maintains Sector Outperform on Hudbay Minerals, Raises Price Target to C$14

Scotiabank analyst Orest Wowkodaw maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Sector Perform and raises the price target from $40 to $43.

Scotiabank Maintains Sector Perform on Freeport-McMoRan, Raises Price Target to $43

Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 28.57 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $513.00 thousand which missed the analyst consensus estimate of $654.00 thousand by 21.56 percent. This is a 36.98 percent decrease over sales of $814.00 thousand the same period last year.

Earnings Misses

NEON

Neonode Q1 EPS $(0.10) Misses $(0.08) Estimate, Sales $513.00K Miss $654.00K Estimate

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
– Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial –
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple abstracts showcasing clinical data for Revuforj&#xAE; (revumenib) and Niktimvo&#x2122; (axatilimab-csfr) were accepted for presentation at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy.

SNDX

Syndax Pharma: Multiple Abstracts Showcasing Clinical Data For Revuforj Accepted For Presentation At EHA Annual Congress Meeting

Primech Holdings Limited ("Primech" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market ("Nasdaq") on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market.&nbsp;

PMEC

Primech Regains Compliance With Nasdaq's Minimum Bid Price Requirement

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) announced Tuesday morning that its CEO, Andrew Witty, <a href="https://www.benzinga.com/quote/UNH/news">will resign for personal reasons..</a>
Stephen Hemsley, who previously held the CEO title from 2006 to 2017, will succeed him. Hemsley will also remain chairman of UnitedHealth's board of directors, and Witty will become senior adviser to the CEO.
The company also revealed that it would suspend its 2025 outlook, citing that care activity continued to accelerate.
UnitedHealth noted broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
It said it "expects to return to growth in 2026," according to the announcement.
The insurance giant reported adjusted EPS of $7.20 in April, up from $6.91 a year ago, missing the consensus of $7.29. Revenues increased 6.8% year over year to $109.6 billion, missing the consensus of $111.60 billion.
UNH shares gained 2.7% to trade at $319.78 on Wednesday.
These analysts made changes to their price targets on UNH following the announcement.
<ul class="wp-block-list">
<li>Keybanc analyst Matthew Gillmor maintained UnitedHealth Group with an Overweight rating and lowered the price target from $575 to $450.</li>
<li>Baird analyst Michael Ha maintained UnitedHealth Group with an Outperform rating and lowered the price target from $510 to $356.</li>
</ul>
Considering buying UNH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-1024x600.png" alt="" class="wp-image-915083" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45402795/top-3-materials-stocks-that-could-blast-off-this-month">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Comments

Kalaris Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO